

Special Issue

Therapeutic Monoclonal Antibodies and Antibody Products, Their Optimization and Drug Design in Cancers

Message from the Guest Editor

Therapeutic monoclonal antibodies (mAbs) are not only dominating the current biologics market but also the mainstay for the development of next-generation biologics as a result of their specificity and selectivity. This Special Issue will cover all aspects of the design, development and optimization of therapeutic monoclonal antibodies. In addition, studies related to protein structure, formulation, pharmacodynamic/pharmacokinetic, immunogenicity, accelerated and prediction results will also be considered. Both experimental and computational approaches can be submitted. **Keywords**

- mAbs / Antibody Optimization / Characterization of Antibodies
- Antibody Medicines / Antibody–Drug Conjugates (ADC)
- Bispecific Antibodies / Multispecific Antibodies
- Next-generation Biologics / Single-domain Antibodies (Nanobodies)
- Follow-on Biologics / Formulation of mAbs
- Biosimilars / Biobetters / Engineering of Antibodies
- Pharmacokinetic and Pharmacodynamic Studies of mAbs
- Modeling and simulation of antibody clearance
- Accelerated Studies of mAbs
- Prediction of Long-term Behavior of mAbs
- Simulation and Experimental Studies of mAbs

Guest Editor

Dr. Veysel Kayser

School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia

Deadline for manuscript submissions

closed (31 July 2019)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/19378

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)